Heron Neutron Medical Corp.
TTWSE:7799430.50
TWD
-9.50
(-2.16%)
ISIN
TW0007799009
Return %
Stock
S&P 500
1Y
-39.96
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Quarterly Revenue
TWD
•
in mil. unless spec.Quarterly Earnings Per Share
TWD
•
in mil. unless spec.Quarterly Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- CEO
- Hsiao Lien Shen
- Full Time Employees
- 111
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Zhubei City Taiwan
- IPO Date
- Sep 15, 2025
- Website
- heron-neutron.com
- Similar Companies
- Business
- Heron Neutron Medical Corp. is a Taiwan-based medical technology company that develops, manufactures, and commercializes accelerator-based boron neutron capture therapy (AB-BNCT) systems and companion radiopharmaceutical solutions for targeted precision oncology. Operating as a consolidated affiliate of the Hermes-Epitek Group, the company delivers an integrated drug-device total solution comprising accelerator-based neutron irradiation systems, including compact cyclotrons, neutron generation target assemblies, beam transport systems, and beam shaping assemblies (BSA); boron-10 therapeutic agents and molecular imaging tracers, such as boronophenylalanine (L-BPA) formulations and 18F-FBPA positron emission tomography (PET) diagnostic agents; proprietary treatment planning systems (TPS), dose calculation software, and real-time beam monitoring suites; patient positioning and immobilization hardware; radiation shielding design and turnkey BNCT treatment center construction services; and ongoing clinical trial support, regulatory advisory, preventative maintenance, and facility operational services. The company operates within the advanced medical equipment and biotechnology sectors, primarily serving tertiary medical centers, cancer research hospitals, and academic oncology institutes. Founded in 2017 and headquartered in Zhubei City, Hsinchu County, Taiwan, the company maintains regional subsidiaries and operating entities across Singapore, Japan, and mainland China to support Asia-Pacific clinical deployments and international commercialization. In recent developments, the company completed its public listing on the Taiwan Stock Exchange (TWSE: 7799) in September 2025; secured medical device market approval and manufacturing certification for its proprietary AB-BNCT irradiation equipment; forged a software integration partnership with Cosylab; entered into a strategic collaboration memorandum of understanding with B dot Medical to explore next-generation particle therapy solutions; established clinical imaging and technology integration with Siemens Healthineers; and advanced turnkey hospital center installations with major regional healthcare providers, including Taipei Veterans General Hospital, China Medical University Hospital, and Nanjing BenQ Medical Center.